» Articles » PMID: 2452199

Antigenic Specificities of Human Monoclonal and Polyclonal IgM Rheumatoid Factors. The C Gamma 2-C Gamma 3 Interface Region Contains the Major Determinants

Overview
Journal J Immunol
Date 1988 May 1
PMID 2452199
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The binding site specificity of 12 monoclonal and 11 polyclonal IgM rheumatoid factors (RF) isolated from human plasma or serum has been studied. All IgM RF bound best to sites on IgG and intact Fc. The monoclonal IgM RF did not bind at all to fragments lacking the C gamma 2 or C gamma 3 domains. In contrast, low level binding to the pFc' fragment, composed of the C gamma 3 domain, was seen with seven IgM RF, mainly from patients with rheumatoid arthritis (RA). IgG1 binding appeared to be a requisite specificity of all human IgM RF. IgM RF binding to IgG3 subclass was common among the monoclonal IgM RF. Most RA polyclonal IgM RF but only 2 of the monoclonal IgM RF possessed the IgG1, 2 and 4 binding pattern. Monoclonal IgM RF which bound best to histidine-modified IgG also bound well to IgG3. The 7-kDa fragment D of staphylococcal protein A inhibited the IgG binding of most monoclonal and to a lesser degree polyclonal IgM RF. Thus, the results indicate that the C gamma 2-C gamma 3 interface region of IgG contains the predominant determinants for monoclonal and polyclonal IgM RF. For some monoclonal IgM RF the binding site, even though at the interface of the C gamma 2 and C gamma 3 domains, is not the staphylococcal protein A site. Furthermore, polyclonal IgM RF possess specificities not encountered among the monoclonal IgM RF. These specificities may have special

Citing Articles

Structural Basis of a Conventional Recognition Mode of IGHV1-69 Rheumatoid Factors.

Shiroishi M Adv Exp Med Biol. 2020; 21:171-182.

PMID: 32185699 DOI: 10.1007/5584_2020_510.


Structure-function analyses of a stereotypic rheumatoid factor unravel the structural basis for germline-encoded antibody autoreactivity.

Shiroishi M, Ito Y, Shimokawa K, Lee J, Kusakabe T, Ueda T J Biol Chem. 2018; 293(18):7008-7016.

PMID: 29523691 PMC: 5936827. DOI: 10.1074/jbc.M117.814475.


Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.

Maeda A, Iwayanagi Y, Haraya K, Tachibana T, Nakamura G, Nambu T MAbs. 2017; 9(5):844-853.

PMID: 28387635 PMC: 5524163. DOI: 10.1080/19420862.2017.1314873.


Elevated Membrane and Soluble CD64: A Novel Marker Reflecting Altered FcγR Function and Disease in Early Rheumatoid Arthritis That Can Be Regulated by Anti-Rheumatic Treatment.

Matt P, Lindqvist U, Kleinau S PLoS One. 2015; 10(9):e0137474.

PMID: 26406605 PMC: 4583189. DOI: 10.1371/journal.pone.0137474.


Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

van Schie K, Wolbink G, Rispens T MAbs. 2015; 7(4):662-71.

PMID: 25962087 PMC: 4623040. DOI: 10.1080/19420862.2015.1048411.